FOLH1 and neoplasm: Another trial is investigating the use of a machine learning algorithm in patients undergoing PET/MRI using [18F]-DCFPyL, a PSMA ligand, in solid tumors including renal masses to assess tumor aggressiveness (NCT04687969).